Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Hollander

Showing results (201-210 of 246) with videos related to

Pageof 25
Sort By:
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 27, 2009
Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative reviewNaomi A Fineberg, Marc N Potenza, Samuel R Chamberlain, et al.
JAMA Psychiatry|July 6, 2022
Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical TrialEric Hollander, Suma Jacob, Roger Jou, et al.
Journal of Obsessive-Compulsive and Related Disorders|January 27, 2025
Yale-Brown Obsessive-Compulsive Scale Modified for Body Dysmorphic Disorder: Factor Structure and Construct Validity of SubfactorsIvar Snorrason, Adam C Jaroszewski, Jennifer L Greenberg, et al.
CNS Spectrums|April 17, 2010
Adequacy of pharmacotherapy among medicaid-enrolled patients newly diagnosed with obsessive-compulsive disorderCheryl S Hankin, Lorrin M Koran, Amy Bronstone, et al.
JAMA Pediatrics|September 25, 2013
Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trialBryan H King, Kimberly Dukes, Craig L Donnelly, et al.
The Journal of Clinical Psychiatry|May 25, 2002
Refractory obsessive-compulsive disorder: state-of-the-art treatmentEric Hollander, Carol A Bienstock, Lorrin M Koran, et al.
Comprehensive Psychiatry|May 10, 2022
Commentary on the article: "Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial" Foa EB et al., JAMA Psychiatry. 2022;79(3):193-200 (1)Naomi A Fineberg, Eric Hollander, Jon E Grant, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 14, 2017
A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum DisorderDaniel Umbricht, Marta Del Valle Rubido, Eric Hollander, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 7, 2016
A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum DisorderDaniel Umbricht, Marta Del Valle Rubido, Eric Hollander, et al.
Brain and Behavior|November 10, 2012
Functional deficits of the attentional networks in autismJin Fan, Silvia Bernardi, Nicholas T Van Dam, et al.
Pageof 25

Showing results (201-210 of 246) with videos related to

Sort By:
Pageof 25
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 27, 2009
Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative reviewNaomi A Fineberg, Marc N Potenza, Samuel R Chamberlain, et al.
JAMA Psychiatry|July 6, 2022
Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder: A Randomized Clinical TrialEric Hollander, Suma Jacob, Roger Jou, et al.
Journal of Obsessive-Compulsive and Related Disorders|January 27, 2025
Yale-Brown Obsessive-Compulsive Scale Modified for Body Dysmorphic Disorder: Factor Structure and Construct Validity of SubfactorsIvar Snorrason, Adam C Jaroszewski, Jennifer L Greenberg, et al.
CNS Spectrums|April 17, 2010
Adequacy of pharmacotherapy among medicaid-enrolled patients newly diagnosed with obsessive-compulsive disorderCheryl S Hankin, Lorrin M Koran, Amy Bronstone, et al.
JAMA Pediatrics|September 25, 2013
Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trialBryan H King, Kimberly Dukes, Craig L Donnelly, et al.
The Journal of Clinical Psychiatry|May 25, 2002
Refractory obsessive-compulsive disorder: state-of-the-art treatmentEric Hollander, Carol A Bienstock, Lorrin M Koran, et al.
Comprehensive Psychiatry|May 10, 2022
Commentary on the article: "Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial" Foa EB et al., JAMA Psychiatry. 2022;79(3):193-200 (1)Naomi A Fineberg, Eric Hollander, Jon E Grant, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 14, 2017
A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum DisorderDaniel Umbricht, Marta Del Valle Rubido, Eric Hollander, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 7, 2016
A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum DisorderDaniel Umbricht, Marta Del Valle Rubido, Eric Hollander, et al.
Brain and Behavior|November 10, 2012
Functional deficits of the attentional networks in autismJin Fan, Silvia Bernardi, Nicholas T Van Dam, et al.
Pageof 25